Spero therapeutics submits new drug application to u.s. fda for tebipenem hbr for the treatment of complicated urinary tract infections including pyelonephritis

Cambridge, mass., oct. 28, 2021 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the submission of a new drug application (nda) to the u.s. food and drug administration (fda), seeking approval for tebipenem hbr tablets for the treatment of complicated urinary tract infections (cuti), including pyelonephritis, caused by susceptible microorganisms. if approved, tebipenem hbr would be the only oral carbapenem antibiotic available for use in cuti.
SPRO Ratings Summary
SPRO Quant Ranking